Login to Your Account

Clinic Roundup

Thursday, June 27, 2013
Labrys Biologics Inc., of San Mateo, Calif., disclosed data from three late-breaking poster presentations demonstrating the pharmacokinetics and safety profile of LBR-101 (formerly RN-307) observed in multiple Phase I trials.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription